What is Oviva?
Oviva operates at the intersection of digital health and personalized nutrition, offering a comprehensive solution for individuals managing chronic conditions such as obesity, diabetes, and food allergies. The company leverages a secure smartphone application to connect patients with professional dietitians, facilitating both in-person and remote consultations. Founded in 2014 and headquartered in Altendorf, Switzerland, Oviva's innovative approach to medical nutritional therapy aims to empower patients with the tools and support needed for sustainable health improvements.
How much funding has Oviva raised?
Oviva has raised a total of $313.8M across 5 funding rounds:
Seed
$800K
Series A
$12M
Series B
$21M
Series C
$80M
Series D
$200M
Seed (2016): $800K, investors not publicly disclosed
Series A (2017): $12M led by F-Prime Capital Partners, Albion Capital Group LLP, Eight Roads Ventures, Walking Ventures, and Partech Ventures
Series B (2020): $21M supported by MTIP, Partech, Eight Roads Ventures, Earlybird, F-Prime Capital, and Albion Capital Group
Series C (2021): $80M featuring Sofina, Eight Roads, Mtip, Temasek, Albion Capital Group, Earlybird, and F-Prime Capital Partners
Series D (2026): $200M backed by Planet First Partners, Sofina, Kinnevik, Lunate, Temasek, Norrsken Vc, EGS Beteiligungen, and AP Moller Group
Key Investors in Oviva
Planet First Partners
Planet First Partners is a growth equity platform focused on investing in and collaborating with disruptive entrepreneurs to scale tech-enabled businesses that prioritize sustainable practices and contribute to a healthier planet.
Kinnevik
Kinnevik is an industry-focused investment company that partners with talented founders to build fast-growing digital consumer businesses, aiming to deliver both shareholder and social value.
Temasek
Temasek is a global investment company headquartered in Singapore, acting as a generational investor focused on making a difference with tomorrow in mind across various sectors.
What's next for Oviva?
The substantial enterprise-level financing, particularly the recent strategic investment, positions Oviva for accelerated expansion and further innovation. This capital infusion is expected to fuel the company's efforts in scaling its digital platform, enhancing its service offerings, and potentially exploring new therapeutic areas or geographical markets. The backing from prominent investors suggests a strong confidence in Oviva's business model and its potential to disrupt traditional healthcare delivery for chronic disease management.
See full Oviva company page
